度普利尤单抗可改善由 2 型炎症引起的获得性反应性穿孔性胶原病。
Dupilumab improve acquired reactive perforating collagenosis characterized by type 2 inflammation.
机构信息
Department of Dermatology, The Eighth Affliated hospital of Sun Yat-sen University, Shenzhen, Guangdong, China.
Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, China.
出版信息
Front Immunol. 2023 Aug 10;14:1240262. doi: 10.3389/fimmu.2023.1240262. eCollection 2023.
BACKGROUND
Acquired reactive perforating collagenosis (ARPC) is a clinically challenging disease with an unclear pathogenesis.
OBJECTIVE
To evaluate the efficacy and safety of dupilumab for the treatment of ARPC, and analyze the expression of type 2 inflammation-related molecules in ARPC lesions.
METHODS
This retrospective cohort study included 20 patients with ARPC; 10 received dupilumab and 10 received conventional therapy. The efficacy and safety of dupilumab were evaluated at 12 weeks. Immunohistochemical and immunofluorescence analyses of T- and B-cell markers, and type 2 inflammation-related cytokines, were performed on skin samples from ARPC patients, atopic dermatitis (AD) patients, and healthy controls.
RESULTS
Significantly more patients showed improvements in the Investigator Global Assessment score (100% vs. 0%; p < 0.0001) and itching (90%/8.33%, P =.001) in the dupilumab group compared to the conventional group at 12 weeks. There were no adverse effects in the dupilumab group. The ARPC lesions showed enhanced dermal infiltration of CD3+ T-cells, with a predominance of Th2 cells, similar to AD lesions. IL-4 and IL-13 were co-localized with GATA3 in ARPC lesions.
CONCLUSION
Dupilumab improved ARPC charaterized with type 2 inflammation.
背景
获得性反应性穿孔性胶原病（ARPC）是一种临床治疗具有挑战性的疾病，其发病机制尚不清楚。
目的
评估度普利尤单抗治疗 ARPC 的疗效和安全性，并分析 ARPC 病变中 2 型炎症相关分子的表达。
方法
本回顾性队列研究纳入了 20 例 ARPC 患者；其中 10 例接受度普利尤单抗治疗，10 例接受常规治疗。在 12 周时评估度普利尤单抗的疗效和安全性。对 ARPC 患者、特应性皮炎（AD）患者和健康对照者的皮肤样本进行 T 细胞和 B 细胞标志物及 2 型炎症相关细胞因子的免疫组化和免疫荧光分析。
结果
与常规组相比，12 周时度普利尤单抗组患者的研究者全球评估评分（100% vs. 0%；p < 0.0001）和瘙痒（90%/8.33%，P =.001）改善更明显。度普利尤单抗组无不良反应。ARPC 病变表现出真皮内 CD3+T 细胞浸润增强，以 Th2 细胞为主，类似于 AD 病变。IL-4 和 IL-13 与 ARPC 病变中的 GATA3 共定位。
结论
度普利尤单抗改善了以 2 型炎症为特征的 ARPC。
Zotero 插件